Tectonic Therapeutic Posts 29.2% PCWP Drop, Initiates PH-ILD and HHT Trials
Tectonic Therapeutic ended 2025 with $253.8 million cash, funding operations into Q4 2028, and reported TX45 Phase 1b results with 29.2% PCWP reduction and 17.3% cardiac output improvement in Group 2 PH-HFrEF. In February 2026 the company initiated a TX45 Phase 2 PH-ILD trial and dosed first subject in the TX2100 Phase 1a HHT study.
1. Financial Position and Runway
Tectonic Therapeutic ended 2025 with $253.8 million in cash and equivalents, providing funding into the fourth quarter of 2028 to support ongoing clinical programs and corporate activities.
2. TX45 Clinical Milestones
TX45 Phase 1b trial in 14 Group 2 PH-HFrEF patients achieved a 29.2% reduction in pulmonary capillary wedge pressure and a 17.3% increase in cardiac output; in February 2026 the company activated the first site for a 16-week Phase 2 trial in PH-ILD with up to 25 patients receiving 300 mg subcutaneously every four weeks, and topline results for the APEX Phase 2 trial in PH-HFpEF are due later in 2026.
3. TX2100 Phase 1a Trial
The TX2100 VHH-Fc fusion antibody targeting the APJ receptor randomized its first healthy volunteer in a double-blind, placebo-controlled Phase 1a trial in February 2026 to evaluate safety, tolerability and pharmacokinetics, with topline data expected in Q4 2026 and a Phase 2 proof-of-concept study planned for early 2027.
4. Board Appointment
François Nader, M.D., MBA, will join the Board of Directors as an independent director and assume the role of Board Chair on April 1, 2026, bolstering governance expertise ahead of key clinical readouts.